Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 28 Feb 2022
Price :
$35
*
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 25 Feb 2022 Planned End Date changed from 1 Sep 2016 to 17 Sep 2016.
- 16 Sep 2020 Results of post-hoc analysis of clinical trials (NCT02337725, NCT02337738) presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 29 Jun 2017 According to a Takeda Pharma media release, based on the data from CCT-001 and CCT-002 studies the company has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare in Japan for rasagiline mesylate for the treatment of Parkinson's disease.